Bruno C Medeiros
Overview
Explore the profile of Bruno C Medeiros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
6047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wuliji N, Jones S, Gooley T, Gerds A, Medeiros B, Shami P, et al.
Blood
. 2025 Mar;
PMID: 40067123
Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH) remains unknown. We examined associations of SDOH with...
2.
Biesdorf C, Guan X, Siddani S, Hoffman D, Boehm N, Medeiros B, et al.
Cancer Chemother Pharmacol
. 2023 Nov;
93(4):329-339.
PMID: 38036720
Purpose: Eftozanermin alfa is a second-generation tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist that enhances death receptor 4/5 clustering on tumor cells to induce apoptosis. We report the pharmacokinetics...
3.
Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, et al.
Leukemia
. 2023 Nov;
38(1):58-66.
PMID: 37935977
Prior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a...
4.
Pousse L, Korfi K, Medeiros B, Berrera M, Kumpesa N, Eckmann J, et al.
Front Oncol
. 2023 May;
13:1150149.
PMID: 37205201
Background: Acute Myeloid leukemia is a heterogeneous disease that requires novel targeted treatment options tailored to the patients' specific microenvironment and blast phenotype. Methods: We characterized bone marrow and/or blood...
5.
Tahir S, Calvo E, Carneiro B, Yuda J, Shreenivas A, Jongen-Lavrencic M, et al.
Blood
. 2023 Jan;
141(17):2114-2126.
PMID: 36720090
Activation of apoptosis in malignant cells is an established strategy for controlling cancer and is potentially curative. To assess the impact of concurrently inducing the extrinsic and intrinsic apoptosis-signaling pathways...
6.
Sorror M, Gooley T, Storer B, Gerds A, Sekeres M, Medeiros B, et al.
Blood
. 2022 Oct;
141(3):295-308.
PMID: 36260765
We designed a prospective, observational study enrolling patients presenting for treatment of acute myeloid leukemia (AML) at 13 institutions to analyze associations between hematopoietic cell transplantation (HCT) and survival, quality...
7.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson R, Ottone T, et al.
Leukemia
. 2022 Aug;
36(9):2218-2227.
PMID: 35922444
The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus...
8.
Daver N, Jonas B, Medeiros B, Patil U, Yan M
Leuk Lymphoma
. 2022 Jul;
63(11):2711-2714.
PMID: 35834732
No abstract available.
9.
Maeng C, Christiansen C, Liu K, Kamper P, Christensen S, Medeiros B, et al.
Leuk Lymphoma
. 2022 May;
63(10):2290-2300.
PMID: 35583300
Identifying risk factors for intensive care unit (ICU) admission in acute leukemia (AL) patients may guide decision-making and improve prognosis. We included all adult AL patients receiving high-intensive chemotherapy in...
10.
Prebet T, Goldberg A, Jurcic J, Khaled S, Dail M, Feng Y, et al.
Leuk Lymphoma
. 2022 May;
63(9):2180-2188.
PMID: 35491816
This phase 1 b study evaluated the safety, efficacy, and pharmacokinetics of atezolizumab in combination with guadecitabine in patients with relapsed/refractory (R/R) or first-line acute myeloid leukemia (AML). Patients received...